![]() |
市場調查報告書
商品編碼
1715311
生物銀行市場按類型、組件、樣本類型、應用、最終用戶、所有者分類——2025-2030 年全球預測Biobanks Market by Type, Component, Sample Type, Application, End User, Ownership - Global Forecast 2025-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計 2024 年生物銀行市場價值為 1,154.3 億美元,到 2025 年將成長至 1,305.6 億美元,複合年成長率為 13.49%,到 2030 年預計將達到 2,467.2 億美元。
主要市場統計數據 | |
---|---|
基準年2024年 | 1154.3億美元 |
預計年份:2025年 | 1305.6億美元 |
預測年份 2030 | 2467.2億美元 |
複合年成長率(%) | 13.49% |
生物庫已成為生物樣本和相關數據的重要儲存庫,為研究、診斷和個人化醫療的突破提供了動力。在當今快速發展的科學環境中,這些設施是支持臨床和轉化研究的創新中心。在過去的十年中,技術進步以及對基因組和分子基礎的深入了解使得生物庫成為戰略資產。這種演變推動了儲存、樣本分析和資料管理的改進,使科學發現更加可靠和可重複。生物庫的更廣泛作用不僅加速了藥物發現,而且對針對患者的治療也做出了巨大貢獻。學術界、生物技術和醫療保健領域的相關人員正在加強合作,以釋放新的可能性,同時應對道德、監管和營運挑戰。隨著市場轉向整合數位平台、強大的基礎設施和先進的分析工具,生物銀行格局即將實現變革性成長。此次招聘既認知到歷史里程碑,也認知到新興趨勢,深入說明市場動態、細分策略和策略考慮,以支持在日益激烈的競爭環境中做出有效決策。
變化中的格局:新趨勢與顛覆性力量
生物銀行生態系統的演變是由一種轉型轉變所驅動的,這種轉變正在重新定義傳統方法,同時為先鋒方法打開大門。即時監控系統、自動化樣本處理和數據分析等技術進步正在重新定義收集和管理實踐。在數位革命中,平台變得越來越互通性和以用戶為中心,使得從樣本到分析的資料流變得快速且安全。監管改革和不斷發展的道德考量也在再形成市場,推動研究機構採用更透明和嚴格的營運框架。同時,隨著學術界、醫院和商業企業重新調整策略以滿足當前和未來的需求,對基因組研究和個人化醫療計劃的投資增加正在進一步刺激這種轉變。此外,全球都專注於發展生物銀行基礎設施,鼓勵私部門和公部門之間的合作。這種環境的特徵是快速適應和策略調整,使市場相關人員能夠克服傳統挑戰並利用新機會。其結果不僅提高了行業標準,而且為全球生物銀行行業的空前成長和協作創新鋪平了道路。
洞察關鍵細分領域 全面多面向分析
生物銀行市場的特徵是複雜而又有洞察力的細分,有利於有針對性的策略和投資。首先從類型上觀察該市場的結構,例如專注於疾病導向模型、基於基因組的方法、基於人群的收集以及日益相關的虛擬生物庫平台的研究。此外,由於市場是透過消耗品、設備和服務進行研究的,因此按組件進行細分也發揮著重要作用。具體而言,設備細分深入到警報和監控系統、培養箱和離心機、溫度控制系統等領域。在服務方面,將嚴格評估資料管理、樣本分析、儲存和處理以及轉運等關鍵業務要素。樣本類型進一步細分為血液、細胞株、核酸和組織,每種都有不同的分析和操作參數。此外,生物銀行應用細分為臨床診斷、個人化醫療、研究和治療,治療領域進一步細分為藥物開發和基因編輯計畫。市場區隔也根據最終用戶細分(例如學術機構、生技公司、醫院、製藥公司等)做出投資決策。市場進一步細分為學術、商業和政府生物庫。這種多方面的細分使我們能夠更深入地挖掘不同的需求和創新軌跡。
The Biobanks Market was valued at USD 115.43 billion in 2024 and is projected to grow to USD 130.56 billion in 2025, with a CAGR of 13.49%, reaching USD 246.72 billion by 2030.
KEY MARKET STATISTICS | |
---|---|
Base Year [2024] | USD 115.43 billion |
Estimated Year [2025] | USD 130.56 billion |
Forecast Year [2030] | USD 246.72 billion |
CAGR (%) | 13.49% |
Biobanks have emerged as vital repositories of biological samples and associated data, fueling breakthroughs across research, diagnostics, and personalized medicine. In today's rapidly evolving scientific environment, these facilities are at the core of innovations that support clinical and translational research. Over the past decade, advancements in technology coupled with an increasing understanding of genomic and molecular underpinnings have positioned biobanks as strategic assets. This evolution has stimulated improvements in storage, sample analysis, and data management, thereby enhancing the reliability and reproducibility of scientific findings. The expansive role of biobanks not only accelerates drug discovery but also contributes significantly to patient-specific therapies. Stakeholders from academia, biotechnology, and healthcare are increasingly collaborating to unlock new possibilities while addressing ethical, regulatory, and operational challenges. As the market shifts toward integrated digital platforms, robust infrastructure, and advanced analytical tools, the biobank landscape is poised for transformative growth. Recognizing both historical milestones and emerging trends, this introduction sets the stage for a detailed exploration of market dynamics, segmentation strategies, and strategic insights that support effective decision-making in an increasingly competitive arena.
Transformative Shifts in the Landscape: Emerging Trends and Disruptive Forces
The evolution of the biobank ecosystem is driven by transformative shifts that reframe traditional methodologies while opening doors to pioneering approaches. Technological advancements, such as real-time monitoring systems, automated sample processing, and data analytics, are redefining collection and management practices. Amid a digital revolution, platforms are becoming more interoperable and user-centric, ensuring that the flow of data from sample collection to analysis is both rapid and secure. Regulatory reforms and evolving ethical considerations are also reshaping the market, prompting institutions to adopt more transparent and rigorous operational frameworks. Concurrently, increased investments in genomic research and personalized healthcare initiatives further stimulate these shifts as academia, hospitals, and commercial ventures recalibrate their strategies to align with present and future demands. In addition, the global focus on developing infrastructure for biobanking has fostered collaborations between private and public sectors. This environment is marked by swift adaptation and strategic realignment, enabling market players to overcome legacy challenges and leverage newfound opportunities. The resulting transformation is not only raising industry standards, but it is also creating pathways for unprecedented growth and collaborative innovation in biobanking worldwide.
Key Segmentation Insights: Comprehensive Analysis Across Multiple Dimensions
The biobank market is characterized by a complex yet insightful segmentation that facilitates targeted strategies and investments. The structure of this market is firstly observed through the perspective of type, with studies focusing on disease-oriented models, genomic-based approaches, population-based collections, and the increasingly relevant virtual biobank platforms. Additionally, segmentation by component plays a crucial role, as the market is examined through consumables, equipment, and services; specifically, equipment segmentation delves into areas such as alarms and monitoring systems, incubators and centrifuges, along with temperature control systems. On the services side, key operational elements such as data management, sample analysis, storage and processing, and transpost are critically evaluated. Further granularity is achieved when considering sample type segmentation, where blood derivatives, cell lines, nucleic acid, and tissues each present distinct analytical and operational parameters. The application of biobanking is also segmented into clinical diagnostics, personalized medicine, research, and therapeutics, with the therapeutics domain further dissected into drug development and gene editing ventures. Market players also align their investment decisions based on end user segments such as academic institutions, biotechnology companies, hospitals, and pharmaceutical companies. Ownership further refines the landscape into academic, commercial, and government biobanks. This multi-dimensional segmentation offers a deep dive into the diverse needs and innovation trajectories that collectively drive the market forward.
Based on Type, market is studied across Disease-Oriented, Genomic-Based, Population-Based, and Virtual.
Based on Component, market is studied across Consumables, Equipment, and Services. The Equipment is further studied across Alarms & Monitoring Systems, Incubators & Centrifuges, and Temperature Control Systems. The Services is further studied across Data Management, Sample Analysis, Storage & Processing, and Transpost.
Based on Sample Type, market is studied across Blood Derivatives, Cell Lines, Nucleic Acid, and Tissues.
Based on Application, market is studied across Clinical Diagnostics, Personalized Medicine, Research, and Therapeutics. The Therapeutics is further studied across Drug Development and Gene Editing.
Based on End User, market is studied across Academic Institutions, Biotechnology Companies, Hospitals, and Pharmaceutical Companies.
Based on Ownership, market is studied across Academic Biobanks, Commercial Biobanks, and Government Biobanks.
Key Regional Insights: Global Diffusion and Local Nuances
Examining the biobank landscape on a global scale unravels significant regional trends and market drivers. In the Americas, a combination of advanced infrastructure, robust funding initiatives, and a well-established network of research institutions creates a fertile ground for biobanking innovation. Both government and private sectors contribute extensively to research support and infrastructure development across these regions, making it a hotspot for cutting-edge developments. In contrast, the Europe, Middle East, and Africa regions exhibit a unique blend of regulatory dynamics and a commitment to traditional as well as pioneering research methodologies. These regions place a strong emphasis on ethical standards and data transparency while steadily advancing their technological capabilities. Meanwhile, the Asia-Pacific market reflects rapid economic growth, a surge in biotechnological investments, and an expanding research framework that is quickly adapting to the demands of modern biobanking. The interplay of local policies, infrastructural investments, and growing public-private partnerships in these regions creates diverse opportunities and challenges, ultimately contributing to the global diffusion and evolution of biobank practices.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Key Companies Insights: Market Leaders Shaping the Competitive Landscape
A number of prominent companies are making substantial contributions to driving growth and innovation within the biobank industry. Leading organizations like Acorn Biolabs, Inc. and AMS Biotechnology (Europe) Limited have carved out niches by providing advanced solutions tailored to specific market needs. Companies such as Artizan Biosciences, Inc. and ASKION GmbH have set exemplary high standards through their commitment to precision and technological advancement. Industry titans including Avantor, Inc. and Bay Biosciences LLC, alongside established brands such as Beckman Coulter, Inc. by Danaher Corporation and Becton, Dickinson and Company, are continuously enhancing operational efficiencies and pushing the boundaries of research solutions. Enterprises like BioIVT LLC, BioKryo by L'AIR LIQUIDE S.A., BioLife Solutions Inc., and BocaBio demonstrate notable strength by integrating innovative technologies into their service offerings. Furthermore, diversified multinational corporations such as Charles River Laboratories International, Inc., Cryoport Systems, LLC, CTIBiotech, and Cureline, Inc. further fortify market competitiveness. Other influential players, including Firalis Group, Greiner AG, Hamilton Company, LVL Technologies GmbH & Co. KG, Merck KGaA, Micronic Holding B.V., ProteoGenex, Inc., Provia Laboratories, LLC, Qiagen N.V., Shanghai Outdo Biotech Co. Ltd, Taylor-Wharton, Tecan Trading AG, Thermo Fisher Scientific Inc., and UK Biobank Limited, continue to drive innovative research and deploy forward-thinking solutions, each leaving a significant imprint on this rapidly maturing market.
The report delves into recent significant developments in the Biobanks Market, highlighting leading vendors and their innovative profiles. These include Acorn Biolabs, Inc., AMS Biotechnology (Europe) Limited, Artizan Biosciences, Inc., ASKION GmbH, Avantor, Inc., Bay Biosciences LLC, Beckman Coulter, Inc. by Danaher Corporation, Becton, Dickinson and Company, BioIVT LLC, BioKryo by L'AIR LIQUIDE S.A., BioLife Solutions Inc., BocaBio, Charles River Laboratories International, Inc., Cryoport Systems, LLC, CTIBiotech, Cureline, Inc., Firalis Group, Greiner AG, Hamilton Company, LVL Technologies GmbH & Co. KG, Merck KGaA, Micronic Holding B.V., ProteoGenex, Inc., Provia Laboratories, LLC, Qiagen N.V., Shanghai Outdo Biotech Co. Ltd, Taylor-Wharton, Tecan Trading AG, Thermo Fisher Scientific Inc., and UK Biobank Limited. Actionable Recommendations for Industry Leaders: Strategic Steps for Future Growth
Industry leaders are advised to adopt comprehensive strategies that address both current challenges and future opportunities in the rapidly evolving biobank market. A primary recommendation is to invest in state-of-the-art technological infrastructure that supports automated processes and real-time monitoring. Embracing digitalization not only enhances operational efficiency but also ensures data integrity and security across the supply chain. Leaders should also consider fostering partnerships with key stakeholders, including academic institutions, biotechnology firms, and healthcare providers, to facilitate knowledge exchange and joint ventures. Building resilient, compliant frameworks that align with stringent regulatory standards is essential; hence, legal and procedural audits should be conducted routinely to uphold transparency and accountability. It is imperative to tailor innovations based on market segmentation insights: customizing solutions to address the varied demands based on type, component, sample type, application, end user, and ownership segments. Furthermore, understanding regional dynamics and adapting to local market conditions will enable more informed decision-making, particularly in diverse territories such as the Americas, Europe, Middle East and Africa, and Asia-Pacific. These strategic recommendations are geared toward positioning companies to capture growth opportunities while mitigating risks in an environment characterized by relentless innovation and changing market paradigms.
Conclusion: Embracing Change and Navigating Future Opportunities
In conclusion, the analysis of the biobank market reveals a vibrant and evolving industry defined by technological innovation, strategic segmentation, and a global spread of opportunities. The comprehensive review provided throughout this document underscores that biobanks are no longer solely repositories for biological samples; they are dynamic entities central to advancements in personalized medicine, clinical diagnostics, and advanced research. With transformative shifts reshaping the market and key players driving technological and operational progress, stakeholders can leverage these insights to navigate the competitive landscape. As emerging trends continue to accelerate, the collective focus on integrating robust infrastructural investments, adhering to stringent regulatory standards, and fostering strategic collaborations will determine the success of industry participants. This evolving market offers both substantial challenges and compelling opportunities, making it imperative for organizations to remain agile and informed as they embark on new initiatives and expansion strategies.